161 related articles for article (PubMed ID: 24517835)
1. Synergism between mTOR pathway and ultraviolet radiation in the pathogenesis of squamous cell carcinoma and its implication for solid-organ transplant recipients.
Balagula Y; Kang S; Patel MJ
Photodermatol Photoimmunol Photomed; 2015 Jan; 31(1):15-25. PubMed ID: 24517835
[TBL] [Abstract][Full Text] [Related]
2. Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control.
Connolly K; Manders P; Earls P; Epstein RJ
Cancer Treat Rev; 2014 Mar; 40(2):205-14. PubMed ID: 24051018
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of p-mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ-transplant recipients.
Karayannopoulou G; Euvrard S; Kanitakis J
Anticancer Res; 2013 Sep; 33(9):3711-4. PubMed ID: 24023300
[TBL] [Abstract][Full Text] [Related]
4. Expression of p53 up-regulated modulator of apoptosis (PUMA) in non-melanoma skin cancer of long-term immunosuppressed solid organ transplant recipients compared to immunocompetent patients.
Neuberger A; Menzer C; Volk N; Enk AH; Hadaschik EN; Lonsdorf AS
Eur J Dermatol; 2021 Oct; 31(5):609-615. PubMed ID: 34903507
[TBL] [Abstract][Full Text] [Related]
5. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study.
Ulrich C; Jürgensen JS; Degen A; Hackethal M; Ulrich M; Patel MJ; Eberle J; Terhorst D; Sterry W; Stockfleth E
Br J Dermatol; 2009 Nov; 161 Suppl 3():78-84. PubMed ID: 19775361
[TBL] [Abstract][Full Text] [Related]
6. mTOR Signalling Pathway-protein Expression in Post-transplant Cutaneous Squamous-cell Carcinomas Before and After Conversion to mTOR-inhibitors.
Koletsa T; Petrakis G; Karayannopoulou G; Euvrard S; Kanitakis J
Anticancer Res; 2018 Jun; 38(6):3319-3322. PubMed ID: 29848679
[TBL] [Abstract][Full Text] [Related]
7. Overview on non-melanoma skin cancers in solid organ transplant recipients.
Forchetti G; Suppa M; Del Marmol V
G Ital Dermatol Venereol; 2014 Aug; 149(4):383-7. PubMed ID: 25068224
[TBL] [Abstract][Full Text] [Related]
8. Mammalian target of rapamycin inhibitors for prolonged secondary prevention of nonmelanoma skin cancer in solid organ transplant recipients.
Gluck M; Hodak E; Davidovici B
Dermatol Ther; 2022 Aug; 35(8):e15649. PubMed ID: 35716099
[TBL] [Abstract][Full Text] [Related]
9. Effector Antitumor and Regulatory T Cell Responses Influence the Development of Nonmelanoma Skin Cancer in Kidney Transplant Patients.
Crespo E; Fernandez L; Lúcia M; Melilli E; Lauzurica R; Penin RM; Quer A; Luque S; Quero M; Manonelles A; Torras J; Cruzado JM; Cañas L; Grinyó JM; Bestard O
Transplantation; 2017 Sep; 101(9):2102-2110. PubMed ID: 28403126
[TBL] [Abstract][Full Text] [Related]
10. Stage-dependent therapeutic efficacy in PI3K/mTOR-driven squamous cell carcinoma of the skin.
Darido C; Georgy SR; Cullinane C; Partridge DD; Walker R; Srivastava S; Roslan S; Carpinelli MR; Dworkin S; Pearson RB; Jane SM
Cell Death Differ; 2018 Jun; 25(6):1146-1159. PubMed ID: 29238073
[TBL] [Abstract][Full Text] [Related]
11. [Organ transplant recipients need intensive control and treatment of skin cancer].
Togsverd-Bo K; Sørensen SS; Hædersdal M
Ugeskr Laeger; 2013 May; 175(20):1408-11. PubMed ID: 23663395
[TBL] [Abstract][Full Text] [Related]
12. Expression and function of macrophage migration inhibitory factor in the pathogenesis of UV-induced cutaneous nonmelanoma skin cancer.
Heise R; Vetter-Kauczok CS; Skazik C; Czaja K; Marquardt Y; Lue H; Merk HF; Bernhagen J; Baron JM
Photochem Photobiol; 2012; 88(5):1157-64. PubMed ID: 22324658
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppression and squamous cell carcinoma: a focus on solid organ transplant recipients.
Herman S; Rogers HD; Ratner D
Skinmed; 2007; 6(5):234-8. PubMed ID: 17786101
[TBL] [Abstract][Full Text] [Related]
14. Histologic features in primary cutaneous squamous cell carcinomas in immunocompromised patients focusing on organ transplant patients.
Smith KJ; Hamza S; Skelton H
Dermatol Surg; 2004 Apr; 30(4 Pt 2):634-41. PubMed ID: 15061848
[TBL] [Abstract][Full Text] [Related]
15. mTOR signaling pathway in penile squamous cell carcinoma: pmTOR and peIF4E over expression correlate with aggressive tumor behavior.
Ferrandiz-Pulido C; Masferrer E; Toll A; Hernandez-Losa J; Mojal S; Pujol RM; Ramon y Cajal S; de Torres I; Garcia-Patos V
J Urol; 2013 Dec; 190(6):2288-95. PubMed ID: 23764082
[TBL] [Abstract][Full Text] [Related]
16. Risk of merkel cell carcinoma after solid organ transplantation.
Clarke CA; Robbins HA; Tatalovich Z; Lynch CF; Pawlish KS; Finch JL; Hernandez BY; Fraumeni JF; Madeleine MM; Engels EA
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25575645
[TBL] [Abstract][Full Text] [Related]
17. Organ transplantation and skin cancer: basic problems and new perspectives.
Hofbauer GF; Bouwes Bavinck JN; Euvrard S
Exp Dermatol; 2010 Jun; 19(6):473-82. PubMed ID: 20482618
[TBL] [Abstract][Full Text] [Related]
18. A population-based study of skin cancer incidence and prevalence in renal transplant recipients.
Moloney FJ; Comber H; O'Lorcain P; O'Kelly P; Conlon PJ; Murphy GM
Br J Dermatol; 2006 Mar; 154(3):498-504. PubMed ID: 16445782
[TBL] [Abstract][Full Text] [Related]
19. The different telomere lengths in basal and squamous cell carcinomas also differ between the nontransplant and renal transplant population.
Perrem K; Lynch A; Al Nooh F; Leader M; Elaine Kay
Hum Pathol; 2008 Jul; 39(7):1034-41. PubMed ID: 18482746
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic features of skin cancer in organ transplant recipients: a retrospective case-control series.
Harwood CA; Proby CM; McGregor JM; Sheaff MT; Leigh IM; Cerio R
J Am Acad Dermatol; 2006 Feb; 54(2):290-300. PubMed ID: 16443060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
